The Exelixis shows a gross margin of 96.3%, an operating margin of 40.2%, an EBITDA margin of 44.8%, and a net margin of 35.5%. Net margin showed the largest year-over-year gain at 5.9 percentage points, whereas gross margin showed the largest decline at 0.3 percentage points.
Over the last 3 years, Exelixis's margins averaged 96.35% gross, 28.88% operating, 34.85% EBITDA, and 25.88% net. The current figures show operating, EBITDA, and net margins are above their three-year averages, while gross margin is below its three-year average.
The strongest improvement was in net margin, which increased by 5.9 percentage points, and operating margin also expanded by 5.2 percentage points and EBITDA margin also expanded by 4.3 percentage points, whereas gross margin contracted by 0.3 percentage points.
Over the last 3 years, the average gross margin for Exelixis was 96.35%. The current gross margin of 96.3% is 0.1 percentage points below its three-year average. Exelixis's gross margin ranged from a low of 95.7% in Mar 2024 to a high of 96.8% in Mar 2025.
Over the last 3 years, Exelixis's operating margin averaged 28.88%. Right now, Exelixis's current operating margin is 40.2%, which is 11.3 percentage points above its three-year average. During this period, operating margin reached a high of 40.2% in Sep 2026 and a low of 9.3% in Dec 2023.
Exelixis's EBITDA margin averaged 34.85% across the past 3 years. Compared with its three-year average, Exelixis's current EBITDA margin is 44.8% and is 10 percentage points above its three-year average. Over the last 3 years, Exelixis's EBITDA margin peaked at 44.8% in Sep 2026 and reached a low of 16.9% in Mar 2024.
Over the last 3 years, Exelixis's net margin averaged 25.88%. As of the latest period, Exelixis's current net margin is 35.5%, which is 9.6 percentage points above its three-year average. During this period, net margin reached a high of 35.5% in Sep 2026 and a low of 11.1% in Mar 2024.
With a gross margin of 96.3%, EXEL stands higher than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 68.3%, Exelixis's gross margin is 41% higher.
As of Sep 30, 2026, EXEL has a gross margin of 96.3%.
As of Sep 30, 2026, EXEL has an operating margin of 40.2%.
The current EBITDA margin for EXEL is 44.8% as of Sep 30, 2026.
The current net margin for EXEL is 35.5% as of Sep 30, 2026.
Across the last 3 years, EXEL averaged 96.4% gross, 28.9% operating, 34.9% EBITDA, and 25.9% net.
Over this 5-year history, EXEL peaked at 96.8% gross in Mar 2025, 40.2% operating in Sep 2026, 44.8% EBITDA in Sep 2026, and 35.5% net in Sep 2026.
In the last 5 years, the lowest margins reported by EXEL were 95.7% gross in Mar 2024, 2.3% operating in Sep 2023, 9.9% EBITDA in Sep 2023, and 5.2% net in Sep 2023.